Asset Details
Do you wish to reserve the book?
Assessing emergence risk of double-resistant and triple-resistant genotypes of Plasmodium falciparum
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Assessing emergence risk of double-resistant and triple-resistant genotypes of Plasmodium falciparum
Do you wish to request the book?
Assessing emergence risk of double-resistant and triple-resistant genotypes of Plasmodium falciparum
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Assessing emergence risk of double-resistant and triple-resistant genotypes of Plasmodium falciparum
2024
Overview
Delaying and slowing antimalarial drug resistance evolution is a priority for malaria-endemic countries. Until novel therapies become available, the mainstay of antimalarial treatment will continue to be artemisinin-based combination therapy (ACT). Deployment of different ACTs can be optimized to minimize evolutionary pressure for drug resistance by deploying them as a set of co-equal multiple first-line therapies (MFT) rather than rotating therapies in and out of use. Here, we consider one potential detriment of MFT policies, namely, that the simultaneous deployment of multiple ACTs could drive the evolution of different resistance alleles concurrently and that these resistance alleles could then be brought together by recombination into double-resistant or triple-resistant parasites. Using an individual-based model, we compare MFT and cycling policies in malaria transmission settings ranging from 0.1% to 50% prevalence. We define a total risk measure for multi-drug resistance (MDR) by summing the area under the genotype-frequency curves (AUC) of double- and triple-resistant genotypes. When prevalence ≥ 1%, total MDR risk ranges from statistically similar to 80% lower under MFT policies than under cycling policies, irrespective of whether resistance is imported or emerges de novo. At 0.1% prevalence, there is little statistical difference in MDR risk between MFT and cycling.
Emergence of malaria parasites resistant to artemisinin has prompted the need for new drug regimens to ensure effective treatment. In this simulation study, the authors evaluate the risk of multidrug resistance under regimens with either concurrent or cyclic use of different first-line therapies.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
Subject
/ Alleles
/ Antimalarials - pharmacology
/ Antimalarials - therapeutic use
/ Cycles
/ Folic Acid Antagonists - therapeutic use
/ Genotype
/ Humanities and Social Sciences
/ Humans
/ Malaria
/ Malaria, Falciparum - drug therapy
/ Malaria, Falciparum - epidemiology
/ Malaria, Falciparum - parasitology
/ Plasmodium falciparum - genetics
/ Policies
/ Risk
/ Science
We currently cannot retrieve any items related to this title. Kindly check back at a later time.